

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**MicroPort Scientific Corporation**

**微創醫療科學有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 00853)**

**MAJOR TRANSACTION  
COMPLETION OF ACQUISITION OF  
THE CRM BUSINESS FROM LIVANOVA PLC**

Reference is made to the announcements dated 20 November 2017, 20 February 2018 and 8 March 2018, the circular dated 3 April 2018 (the “**Circular**”) and the poll results announcement dated 19 April 2018 of MicroPort Scientific Corporation (the “**Company**”) in relation to the proposed acquisition of the CRM Business from LivaNova PLC. Unless otherwise stated, capitalised terms used in this announcement shall have the same meanings as defined in the Circular.

**COMPLETION OF ACQUISITION OF THE CRM BUSINESS**

The Board is pleased to announce that all the conditions precedents to completion of the Acquisition have been fulfilled and the Acquisition was completed on 30 April 2018.

Following completion of the Acquisition, the financial results of the CRM Business will be consolidated into the financial statements of the Group.

The Board wishes to inform the Shareholders that it has been informed by the Seller that, on 19 April 2018, an investigation has been initiated by a regional antitrust authority in France into the French cardiac rhythm management market, and a subsidiary of the CRM Business operating the business in Clamart, France is one of the companies being investigated. The subsidiary under investigation believes it is in full compliance with all applicable laws and is and intends to continue to cooperate with the relevant authorities. Nevertheless, the Seller has agreed to provide a limited indemnity to the Purchaser of generally up to €16.5 million relating to such investigation. The Board considers that such indemnity is in the interest of the Company and its Shareholders.

Save as disclosed above, all the terms of the Acquisition remain the same in all material respects.

By Order of the Board  
**MicroPort Scientific Corporation**  
**Dr. Zhaohua Chang**  
*Chairman*

Shanghai, the People's Republic of China, 30 April 2018

*As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Norihiro Ashida, Mr. Hiroshi Shirafuji, Ms. Janine Junyuan Feng and Ms. Weiwei Chen; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.*

\* *for identification purpose only*